Hatice Bilge AÇIK, Mehmet Salih AYDIN, Mustafa GÖZ, MAHMUT PADAK, REŞAT DİKME, ÖMER GÖÇ

Kardiyopulmoner Baypass Sırasında Homosistein, Vitamin B12 ve Folik Asit Seviyelerinin Değişimi ve Birbirleri ile Olan İlişkilerinin İncelenmesi

Amaç: Yaptığımız bu çalışmada Kardiyopulmoner bypass (KPB) sırasında homosistein, vitamin B12 ve folik asit parametrelerinin değişimlerine bakılarak birbirleri ile olan ilişkilerinin araştırılması amaçlanmıştır. Yöntemler: Göğüs Kalp Damar Cerrahisi bölümünde çeşitli sebeplerden dolayı KPB cerrahisi ile ameliyat olan hastalardan ameliyat öncesi, pompaya (kalp akciğer makinesi) giriş, kross klemp sonrası ve protamin verilmesi sonrası olmak üzere 4 jelsiz tüpe kan alınarak bir çalışma grubu oluşturuldu. Alınan kanlarda serum Vitamin B12 düzeyi ve serum Folik asit düzeyi Kemilüminesans yöntemi ile serum Homosistein düzeyi ise Kolorimetrik yöntem ile ölçülmüştür. Bulgular: Vitamin B12, pg/MI değeri; Ameliyat öncesi 206.30 ±64.76, Pompaya Giriş108.03 ± 35.75, Kross Klemp Sonrası 128.53 ± 38.43, Protamin Sonrası 141.33 ± 39.21, p

Investigation of the Relationship Between Homocysteine, Vitamin B12 and Folic Acid Levels and their Relationship between the Cardiopulmonary Bypass

Objective: The aim of this study was to investigate the association between homocysteine, vitamin B12 and folic acid parameters in cardiopulmonary bypass (CPB). Methods: In the thoracic cardiovascular surgery department, a study group was formed by taking 4 gel-free scales from pre-operative, pump (heart lung machine), after cross-clamp and protamine administration from patients who underwent surgery with CPB surgery for various reasons. Serum vitamin B12 level and serum Folic acid level were measured by chemiluminescence method and serum homocysteine level by Colorimetric method. Results: Vitamin B12, pg / mL value; Preoperatively 206.30 ± 64.76, Pump Entry 108.03 ± 35.75, Post Cross Clamp 128.53 ± 38.43, Post Protamine 141.33 ± 39.21, p

PDF

___

1.Fattal-Valevski A, Bassan H, Korman SH, et all. Methylenetetrahydrofolate reductase deficiency: importance of early diagnosis. J Child Neurol. 2000; 15: 539-43.
2. Cumming AM, Olujohungbe A, Keeney S, et all. The methylenetetrahydrofolate reductase gene C677T polymorphism in patients with homozygous sickle cell disease and stroke. Br J Haematol. 1999; 107: 569-71.
3. Markus HS, Ali N, Swaminathan R, et all. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke. 1997; 28: 1739-43.
4. Utku U, Çelik Y. Serebrovasküler hastalıklar. In: Balkan S, ed. Ankara: Güneş Kitapevi. 2002: 49-61.
5. Hademenos GJ, Alberts MJ, Awad I, et all. Advances in the genetics of cerebrovascular disease and stroke. Neurology. 2001: 24; 56: 997-1008. Review.
6. Kostulas K, Crisby M, Huang WX, et all. A methylenetetrahydrofolate reductase gene polymorphism in ischaemic stroke and in carotid artery stenosis. Eur J Clin Invest. 1998; 28: 285-9.
7. Engbersen AM, Franken DG, Boers GH, et all. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet. 1995; 56: 142-50.
8. Sucu M, Karadere A, Toprak N. Homosistein ve kardiyovasküler hastalıkları. Türk Kardiyol Dern Arş. 2001; 29: 181-90.
9. Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. A case-control study. Circulation. 1996; 15; 94: 1812-4.
10. Dekou V, Whincup P, Papacosta O, et all. The effect of the C677T and A1298C polymorphisms in the methylenetetrahydrofolate reductase gene on homocysteine levels in elderly men and women from the British regional heart study. Atherosclerosis. 2001; 15; 154: 659-66.
11. Tice JA, Ross E, Coxson PG, et all. Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. JAMA. 2001; 22-29; 286: 936-43.
12. Fallon UB, Ben-Shlomo Y, Elwood P, Ubbink JB, Smith GD. Homocysteine and coronary heart disease in the Caerphilly cohort: a 10 year follow up. Heart. 2001; 85: 153-8.
13. Jacques PF, Bostom AG, Williams RR, et all. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996: 1; 93: 7-9.
14. Nygård O, Nordrehaug JE, Refsum H, et all. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997: 24; 337: 230-6.
15. Sakurabayashi T, Fujimoto M, Takaesu Y, et all. Association between plasma homocysteine concentration and carotid atherosclerosis in hemodialysis patients. Jpn Circ J. 1999; 63: 692-6.
16. Clarke R, Daly L, Robinson K, et all. Graham Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991: 25; 324: 1149-55.
17. Ranucci M, Ballotta A, Frigiola A, et all. Pre-operative homocysteine levels and morbidity and mortality following cardiac surgery. Eur Heart J. 2009 Apr; 30: 995-1004. doi: 10.1093/eurheartj/ehp015. Epub 2009; 17.
18. Nygård O, Nordrehaug JE, Refsum H, et all. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997: 24; 337: 230-6.
19. Dhamija RK, Gaba P, Arora S, et all. Homocysteine and lipoprotein (a) correlation in ischemic stroke patients. J Neurol Sci. 2009 Jun 15; 281: 64-8. doi: 10.1016/j.jns.2009.02.341. Epub 2009;13.
20. J. Auer, R. Berent, B. Eber: Homocysteine: a novel risk factor in vascular disease. Coronary Health Care 2001; 5: 89-99.
21. Medical Biochemistry, N. V. Bhagavan, Fourth Edition, Sayfa: 354-6.
22. Chao CL, Kuo TL, Lee YT: Effects of methionineinduced hyperhomocysteinemia on endotheliumdependent vasodilation and oxidative status in healthy adults. Circulation 2000; 101: 485-90.
23. Outinen PA, Sood SK, Liaw PC, et all.: Characterization of the stressinducing effects of homocysteine. Biochem J 1998; 332: 213-21.
24. Jakubowski H: Metabolism of homocysteine thiolactone in human cell cultures. Possible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem 1997; 272: 1935-42.
25. Loscalzo J: The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 5-7.
26. Ranucci M, Frigiola A, Menicanti L, et all.: Postoperative antithrombin levels and outcome in cardiac operations. Crit Care Med 2005; 33: 355-360.
27. Ranucci M, Ditta A, Boncilli A, et all.: Determinants of antithrombin consumption in cardiac operations requiring cardiopulmonary bypass. Perfusion 2004; 19: 47-52.
28. Ranucci M, Ballotta A, Frigiola A, et all.: Preoperative homocysteine levels and morbidity and mortality following cardiac surgery. Eur Heart J 2009; 30: 995– 1004.